Fidelis Capital Partners, LLC Eagle Pharmaceuticals, Inc. Transaction History
Fidelis Capital Partners, LLC
- $702 Billion
- Q2 2024
A detailed history of Fidelis Capital Partners, LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Fidelis Capital Partners, LLC holds 12,762 shares of EGRX stock, worth $54,621. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,762Holding current value
$54,621% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding EGRX
# of Institutions
79Shares Held
9.89MCall Options Held
1.01MPut Options Held
0-
Nantahala Capital Management, LLC New Canaan, CT1.96MShares$8.4 Million0.73% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.21MShares$5.19 Million2.46% of portfolio
-
Citigroup Inc1MShares$4.29 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT697KShares$2.98 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA564KShares$2.42 Million0.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $55.7M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...